Hoth Therapeutics, Inc HOTH 深 滬
等待開盤 06-25 09:30:00 美东时间
1.36
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 1.36
- 總市值 2601.36万
- 52周最高 2.115
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.4894
- 委 比 0.00%
- 總股本 1912.76万
- 歷史最高 347.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.4894
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rocket One regains full Nasdaq compliance
Rocket One (NASDAQ: RKTO) announced on Wednesday that Nasdaq notified the company it has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2). The company met the r...
06-24 20:50
Hoth Therapeutics Announces That Previously Disclosed Name Change To Rocket One, Trading Under Symbol 'RKTO,' To Take Effect May 28
Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("Hoth" or the "Company") today announced that, following the strategic repositioning disclosed on May 19, 2026, it has completed the legal change of its corporate name to Rocket One
05-27 20:18
Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform
Allowed Claims Cover Composition-of-Matter and Methods Targeting MS4A6A Pre-mRNA Splicing to Reduce Surface Expression of the High-Affinity IgE Receptor (FcεRI); Strengthens Intellectual Pro...
05-26 20:18
EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies
Hoth Therapeutics plans Rocket One rebrand to pursue AI semiconductor and spintronic computing opportunities.
05-19 19:46
Hoth Therapeutics Q1 EPS $(0.17) Up From $(0.27) YoY
Hoth Therapeutics (NASDAQ:HOTH) reported quarterly losses of $(0.17) per share. This is a 37.04 percent increase over losses of $(0.27) per share from the same period last year.
05-16 06:02
Hoth Therapeutics Launches Rocket One Space Subsidiary Initiative
The latest update is out from Hoth Therapeutics ( ($HOTH) ). On April 22, 2026,...
05-07 04:59
Hoth Therapeutics Secures Regulatory Authorization In Spain For Phase 2a CLEER Trial Of HT-001
Regulatory Clearance in Spain Advances Randomized, Placebo-Controlled Study; Patients Show Meaningful Reductions in EGFR-Inhibitor Skin Toxicities with No Treatment DisruptionsNEW YORK, May 5, 2026 /PRNewswire/ --
05-06 04:29
Hoth Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice
An update from Hoth Therapeutics ( ($HOTH) ) is now available. On April 30, 202...
05-05 07:15
Hoth Therapeutics Announces Data From Its HT-VA Study Demonstrating That Parenteral GDNF Directly Reprograms Liver Fat Metabolism At The Genetic Level In A Preclinical Model of Metabolically Associated Fatty Liver Disease
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company, today announced positive data from its HT-VA study, conducted under its Cooperative Research and Development Agreement (CRADA) with the
04-14 05:27
Hoth Therapeutics Announces $2M Direct Offering At $0.70/Shr
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced that it has entered into a definitive agreement for
04-02 01:56
